Terminalia catappa Fruit Extract Reverses Streptozotocin-Induced Diabetic Retinopathy in Rats
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
OBJECTIVE AND BACKGROUND: Diabetic retinopathy is amongst the most common microvascular complications associated with diabetes. Controlling blood glucose level alone cannot manage diabetes associated complications. Thus, mechanisms that additionally prevent diabetes associated complications are the need of the hour, driving the researchers towards herbal therapies. Terminalia catappa is renowned for its anti-inflammatory, antioxidant, anti-hyperglycemic and anti-angiogenic activity. The current study explores the effect of Terminalia catappa fruit extract on streptozotocin-induced diabetic retinopathy in rats.
METHODS: Streptozotocin-induced chronic diabetic rat model was utilized in the study. The hydroalcoholic fruit extract of T. catappa in 20mg/kg, 30mg/kg and 40mg/kg dose and standard anti-diabetic drug, glibenclamide (10mg/kg) was given orally. Retinopathy was evaluated by monitoring lenticular, fundus images and measuring arteriole and venule tortuosity index. Oxidative, angiogenic and inflammatory biomarkers were assessed at the 12th week in the retinal homogenate. Histopathological changes in the retina were also examined. Data was analyzed using one-way Repeated Measure ANOVA followed by the Mann-Whitney test.
RESULTS: The hydro-alcoholic fruit extract of T. catappa significantly decreased blood glucose (p<0.001) in a dose-dependent manner in diabetic rats. Cataract lens was observed in all experimental groups and became clear (grade 0) with 40mg/kg and with 40mg/kg along with glibenclamide at the eighth and sixth week, respectively. The hydro-alcoholic fruit extract in all three doses significantly reduced (p<0.01) arteriole and venule tortuosity in diabetic rats. T. catappa in all three doses in diabetic rats showed a modulatory effect in oxidative, angiogenic and inflammatory biomarkers.
CONCLUSION: T. catappa reverses diabetes-induced retinopathy by anti-hyperglycemic, anti-oxidant, anti-angiogenic and anti-inflammatory actions, and thus has a potential to be used in diabetes-induced retinopathy.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
---|---|
Enthalten in: |
Endocrine, metabolic & immune disorders drug targets - 21(2021), 6 vom: 29., Seite 1053-1065 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Behl, Tapan [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 07.01.2022 Date Revised 07.01.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.2174/1871530320666201029142113 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM316899631 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM316899631 | ||
003 | DE-627 | ||
005 | 20231225162100.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2174/1871530320666201029142113 |2 doi | |
028 | 5 | 2 | |a pubmed24n1056.xml |
035 | |a (DE-627)NLM316899631 | ||
035 | |a (NLM)33121423 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Behl, Tapan |e verfasserin |4 aut | |
245 | 1 | 0 | |a Terminalia catappa Fruit Extract Reverses Streptozotocin-Induced Diabetic Retinopathy in Rats |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 07.01.2022 | ||
500 | |a Date Revised 07.01.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
520 | |a OBJECTIVE AND BACKGROUND: Diabetic retinopathy is amongst the most common microvascular complications associated with diabetes. Controlling blood glucose level alone cannot manage diabetes associated complications. Thus, mechanisms that additionally prevent diabetes associated complications are the need of the hour, driving the researchers towards herbal therapies. Terminalia catappa is renowned for its anti-inflammatory, antioxidant, anti-hyperglycemic and anti-angiogenic activity. The current study explores the effect of Terminalia catappa fruit extract on streptozotocin-induced diabetic retinopathy in rats | ||
520 | |a METHODS: Streptozotocin-induced chronic diabetic rat model was utilized in the study. The hydroalcoholic fruit extract of T. catappa in 20mg/kg, 30mg/kg and 40mg/kg dose and standard anti-diabetic drug, glibenclamide (10mg/kg) was given orally. Retinopathy was evaluated by monitoring lenticular, fundus images and measuring arteriole and venule tortuosity index. Oxidative, angiogenic and inflammatory biomarkers were assessed at the 12th week in the retinal homogenate. Histopathological changes in the retina were also examined. Data was analyzed using one-way Repeated Measure ANOVA followed by the Mann-Whitney test | ||
520 | |a RESULTS: The hydro-alcoholic fruit extract of T. catappa significantly decreased blood glucose (p<0.001) in a dose-dependent manner in diabetic rats. Cataract lens was observed in all experimental groups and became clear (grade 0) with 40mg/kg and with 40mg/kg along with glibenclamide at the eighth and sixth week, respectively. The hydro-alcoholic fruit extract in all three doses significantly reduced (p<0.01) arteriole and venule tortuosity in diabetic rats. T. catappa in all three doses in diabetic rats showed a modulatory effect in oxidative, angiogenic and inflammatory biomarkers | ||
520 | |a CONCLUSION: T. catappa reverses diabetes-induced retinopathy by anti-hyperglycemic, anti-oxidant, anti-angiogenic and anti-inflammatory actions, and thus has a potential to be used in diabetes-induced retinopathy | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Diabetes | |
650 | 4 | |a Terminalia catappa | |
650 | 4 | |a angiogenesis | |
650 | 4 | |a diabetic retinopathy | |
650 | 4 | |a inflammation | |
650 | 4 | |a oxidative stress. | |
650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
650 | 7 | |a Antioxidants |2 NLM | |
650 | 7 | |a Blood Glucose |2 NLM | |
650 | 7 | |a Hypoglycemic Agents |2 NLM | |
650 | 7 | |a Plant Extracts |2 NLM | |
650 | 7 | |a Streptozocin |2 NLM | |
650 | 7 | |a 5W494URQ81 |2 NLM | |
700 | 1 | |a Velpandian, Thirumurthy |e verfasserin |4 aut | |
700 | 1 | |a Kotwani, Anita |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Endocrine, metabolic & immune disorders drug targets |d 2006 |g 21(2021), 6 vom: 29., Seite 1053-1065 |w (DE-627)NLM161976174 |x 2212-3873 |7 nnns |
773 | 1 | 8 | |g volume:21 |g year:2021 |g number:6 |g day:29 |g pages:1053-1065 |
856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871530320666201029142113 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 21 |j 2021 |e 6 |b 29 |h 1053-1065 |